The company will present Proliv Rx, its FDA-approved physician-directed neuromodulation therapy for adults with major depressive disorder who have not responded adequately to antidepressant medication. ...
The recognition places Caracal’s nitrile examination glove within a vetted category of medical products meeting sustainability and safer chemical criteria for healthcare procurement. ...
Expansion of Duke-NUS’ Pathways to Medicine programme lets more aspiring doctors pursue diverse academic interests before joining medical school....
The FDA marketing authorisation establishes a new Class II device category for Aurie’s automated reusable no-touch intermittent urinary catheter system, with launch planned in Veterans Health Administration spinal cord injury hospitals later this year. ...
Mason has more than 25 years of experience in the medical device industry and more than a decade of executive-level healthcare leadership expertise...
The NMPA designation advances NHWD-870 HCI, an oral BET inhibitor for advanced thoracic NUT carcinoma, following Phase II data showing anti-tumour activity and survival benefit in a rare, aggressive cancer with limited treatment options. ...
The Tokyo office will support Japanese biopharmaceutical companies across the product lifecycle, combining market access, medical, marketing and strategic consulting capabilities under the leadership of Junji Yokokawa. ...
India Sebia, in collaboration with CAHO Diagnostic Division, is proud to announce the launch of the Autoimmunity Masterclass Series—a six-part academic webinar initiative aimed at advancing the understanding, early diagnosis, and clinical management of autoimmune diseases....
The redesigned website expands clinical evidence, workflow guidance and access pathways for the Vivio System, an FDA-cleared non-invasive device used to measure elevated left ventricular end-diastolic pressure in outpatient settings. ...
The NMPA acceptance of Chance Pharma’s first new drug application advances CXG87, an improved budesonide/formoterol dry powder inhalation therapy, toward potential commercialisation in China. ...
